Navigation Links
Kosan's Second-Generation Hsp90 Inhibitor, Alvespimycin, Shows 42% Clinical Benefit in Phase 1 HER2-Positive Metastatic Breast Cancer Trial
Date:9/10/2007

Data Presented at ASCO Breast Cancer Symposium; Additional Positive Results

Seen Since Presentation at ASCO Annual Meeting in June Phase I Trial Expanding to Include Alvespimycin Plus Trastuzumab Plus

Paclitaxel Regimen

HAYWARD, Calif., Sept. 10 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated (Nasdaq: KOSN) presented updated data from a Phase 1 clinical trial showing that alvespimycin, its second-generation Hsp90 inhibitor, demonstrated antitumor activity and tolerability in combination with trastuzumab (Herceptin(R)) in patients with refractory HER2-positive metastatic breast cancer, and in patients with refractory ovarian cancer who were progressing on standard chemotherapy. Data from the ongoing trial in patients with solid tumors were presented on Friday, September 7, 2007 by Shanu Modi, M.D., Memorial Sloan Kettering Cancer Center, in a poster, titled, "Alvespimycin (KOS-1022) and Trastuzumab (T): Activity in HER2+ Metastatic Breast Cancer (MBC)" at the 2007 Breast Cancer Symposium of the American Society of Clinical Oncology (ASCO), San Francisco, CA.

"Alvespimycin continues to demonstrate meaningful antitumor activity in patients with highly refractory HER2-positive metastatic breast cancer and ovarian cancer, with additional positive Phase 1 data showing sustained responses and clinical benefit," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "Our strategy is to pursue potentially a broad and fast-to-market development pathway for alvespimycin in HER2-positive metastatic breast cancer. We are expanding the Phase 1 trial to include an alvespimycin plus trastuzumab plus paclitaxel regimen to establish a saf
'/>"/>

SOURCE Kosan Biosciences Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
2. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
6. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
7. Clinical Data on ARIADs Novel mTOR Inhibitor, AP23573, To Be Presented at the ASCO Annual Meeting
8. ArQule Announces Acceptance of Clinical Data on ARQ 197, c-Met Inhibitor, for Oral Presentation at ASCO
9. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
10. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
11. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 2014  PTC Therapeutics, Inc. (NASDAQ: PTCT ... webcast conference call to report its second quarter 2014 ... business and outlook on Thursday, August 7, 2014 at ... The call can be accessed by ... minutes prior to the start of the call and ...
(Date:7/24/2014)... Wis. , July 24, 2014  Restore ... specialty and compounded pharmaceuticals, announced that it is ... information unique to each individual based upon their ... possible by understanding the interaction between a patient,s ... "We,re very excited to provide this new ...
(Date:7/24/2014)... HILDEN , Deutschland, und ... , ... ermöglicht QIAGEN die Entwicklung von ... Genpanels, für Blutkrebs  Neuer Test ... Patienten mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
... & Sullivan honors KJAYA Medical with ... Innovation Award in Web-based Medical Imaging Data Management ... For the first time, medical facilities can manage ... industry-standard applications, leading-edge 3D processing, PET/CT analysis and ...
... Nov. 22, 2011 Reportlinker.com announces ... is available in its catalogue: ... Global Pipeline Analysis, Opportunity Assessment and ... http://www.reportlinker.com/p0685950/Spinal-Non-Fusion-Devices---Global-Pipeline-Analysis-Opportunity-Assessment-and-Market-Forecasts-to-2017.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Orthopedic ...
Cached Medicine Technology:KJAYA Medical Honored with 2011 Frost & Sullivan Award for Technology Innovation in Web-based Medical Imaging Data Management 2Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 2Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 3Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 4Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 5Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 6Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 7Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 8Spinal Non-Fusion Devices - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2017 9
(Date:7/24/2014)... THURSDAY, July 24, 2014 (HealthDay News) -- A new ... abusers from snorting or injecting the drug has been ... Called Targiniq ER and made by Purdue Pharma, the ... naloxone, a drug that blocks the euphoric effects of ... is crushed, snorted, dissolved or injected, according to the ...
(Date:7/24/2014)... Annual National Venous Interventional Summit is available at: ... established Venous Endovascular Interventional Strategies group comprised of ... to provide a "How To" meeting for cardiologists ... advancing their knowledge and skills in venous interventions ... comprehensive venous interventional program. Topics at this year,s ...
(Date:7/24/2014)... 2014 ACRIA & AMIDA CARE TO COHOST ... , Save the Dates: August 7th & August 8th* ... cohost “A Dialogue for Life” forums this August, led by ... Office of National AIDS Policy (ONAP). This will be a ... locally by AIDS organizations, consumers and advocates to advance the ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 National Analysts ... announced that it will operate globally under the name, ... remains a woman-owned Employee Stock Ownership Plan (ESOP) organization ... Schwartz McDonald, Ph.D . The firm guides market ... powerful analytics. , Said McDonald, “We wanted our ...
(Date:7/24/2014)... July 24, 2014 For the first time in ... United States. The Scottish singer first became a known musical commodity ... Her first song on the show was “I Dreamed a Dream,” ... released five studio albums since her time on the reality show ... in front of her American fans. The tour will kick off ...
Breaking Medicine News(10 mins):Health News:FDA Approves Hard-to-Abuse Narcotic Painkiller 2Health News:Preliminary agenda available for 4th VEINS Conference to be held October 9-12 in Chicago 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 2Health News:White House Office of National AIDS Policy Hosts Public Forums in NYC Aug. 7 and 8, Sponsored by Amida Care and ACRIA 3Health News:National Analysts Worldwide Announces a Change of Name to NAXION 2Health News:National Analysts Worldwide Announces a Change of Name to NAXION 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 2Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 3Health News:Susan Boyle Tickets: Dazzling Deals Tickets Cuts Ticket Prices for Susan Boyle's 2014 North America Concert Tour 4
... coverage with 99.99% ... captioning uptime, CANONSBURG, ... watched news reports, exit polls, and,election results for hundreds of national, ... networks and local stations,across the country, VITAC realtime captioners provided English ...
... financial advisor with,Minneapolis-based North Star Resource Group, has been ... Doctors" in 2008. The list of,top advisors will appear ... on,nominations from clients and survey data completed by advisors., ... said Dave,Vasos, co-president and chief financial officer of North ...
... The,patient-centered medical home, personal health records and emergency,department ... "Best in,Medicine" conference presented by the Michigan State Medical ... 3:30 p.m. at The Inn at St. John,s,in Plymouth., ... benefits and,cost-savings of the emerging health care model that ...
... Quarter Highlighted by Submission of NDA for Novel Antidepressant and ... Steady Global Growth for Once-Daily Tramadol - ... DDS;,NASDAQ: DDSS) today reported its results for the third quarter ... otherwise,stated., "We are very pleased with the progress of ...
... 7 EntreMed, Inc.,(Nasdaq: ENMD ) a ... cancer and inflammatory diseases,announced today that James S. ... Company update at the Rodman and Renshaw 10th ... 2008 at the New,York Palace Hotel in New ...
... same quarter in Fiscal 2008 -, (all ... BELLEVILLE, ON, Nov. 7 /PRNewswire-FirstCall/ - Bioniche ... company, today announced financial results for the first,quarter ... 2008., "Our revenues are up by 37% ...
Cached Medicine News:Health News:Flawless Captioning Service Brings Obama Victory and Speech to Deaf and Hard-Of-Hearing Viewers 2Health News:Andy Tate, North Star Resource Group Advisor, Named One of Medical Economics' '150 Best Financial Advisors for Doctors' 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 2Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 3Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 4Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 5Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 6Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 7Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 8Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 9Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 10Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 11Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 12Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 13Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 14Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 15Health News:Labopharm Reports Results for Third Quarter Fiscal 2008 16Health News:EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference 2Health News:Bioniche Reports Fiscal 2009 First Quarter 2Health News:Bioniche Reports Fiscal 2009 First Quarter 3Health News:Bioniche Reports Fiscal 2009 First Quarter 4Health News:Bioniche Reports Fiscal 2009 First Quarter 5Health News:Bioniche Reports Fiscal 2009 First Quarter 6Health News:Bioniche Reports Fiscal 2009 First Quarter 7Health News:Bioniche Reports Fiscal 2009 First Quarter 8Health News:Bioniche Reports Fiscal 2009 First Quarter 9Health News:Bioniche Reports Fiscal 2009 First Quarter 10Health News:Bioniche Reports Fiscal 2009 First Quarter 11Health News:Bioniche Reports Fiscal 2009 First Quarter 12
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: